2013 Archived Content
Seventh Annual

Cancer Molecular Markers

Advancing Personalized Medicine

 

Day 1 | Day 2 | Day 3 

Thursday, February 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee





 
8:00 - 9:40 Plenary Keynote Panel: Emerging Technologies & Industry Perspectives 

This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included. - Read more 

Sponsored by


 

 

Biocartis  Elsevier  Luminex  RemedyMD  Scientia Advisors  Singulex 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

 

FFPE Samples 

10:40 Chairperson’s Remarks

James C. Willey, M.D., Professor, Medicine and Pathology, University of Toledo College of Medicine; Consultant, Accugenomics, Inc.

10:45 Deep Sequencing of DNA and RNA from FFPE Samples

Toumy Guettouche, Ph.D., Assistant Professor, Hussman Institute for Human Genomics, Dr. John T. MacDonald Foundation Department of Human Genetics; Director, Genome Technology Assessment and Implementation, Center for Genome Technology; Director, Oncogenomics Core Facility, Sylvester Comprehensive Cancer Center, University of Miami, School of Medicine
 

11:15 Molecular Tools for Pathology Diagnostics: Requirements in Terms of Turnaround Time, Specimens, and Quality Assurance

Daniëlle A.M. Heideman, Ph.D., Assistant Professor, Department of Pathology, Molecular Pathology Unit, VU University Medical Center

The increasing knowledge about cancer biology and the development of targeted therapies have initiated a revolution in pathology: malignancies are increasingly classified and treated according to their biomarkers. Important aspects to consider for molecular diagnostics in pathology will be discussed in this presentation. With focus on mutation analysis, aspects like specimen type, quality assurance, and turnaround time will be considered.
 

11:45 Molecular Diagnostic Tests to Augment Cytomorphologic Diagnosis of Lung Cancer

James C. Willey, M.D., Professor, Medicine and Pathology, University of Toledo College of Medicine; Consultant, Accugenomics, Inc.

An approach that overcomes a common obstruction to development and commercialization of new molecular diagnostic tests: lack of robustness sufficient to enable reliable implementation in surgical and needle aspiration cell block FFPE samples.

ATCC12:15 pm ATCC Molecular Signature Tumor Cell Panels for Drug ScreeningPhillip Wang, Ph.D., Business Marketing Manager, ATCCHuman tumor derived cell lines play key roles in understanding cancer biology and developing novel therapeutics. This presentation introduces how validated, assay-ready tumor cell line panels provide a quick and convenient method suitable for high-throughput screening and mechanism studies. In particular, this presentation describes the breast cancer cell line panel, which represents the major clinical manifestation. In addition, the application of tissue specific tumor cell panels and molecular signature tumor cell panels in cancer research will be discussed.

12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own 

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

 

Single Cell Analyses 

1:40 Chairperson’s Remarks

1:45 Single Cell Profiling of Circulating Tumor Cells

Stefanie Jeffrey, M.D., John and Marva Warnock Professor, Department of Surgery, Chief of Surgical Oncology Research, Stanford University School of Medicine

2:15 Microtechnologies to Interrogate Signaling in Single Cells

Nancy Allbritton, M.D., Ph.D., Professor & Chair, UNC/NCSU Department of Biomedical Engineering; Chair, UNC CASE; Department of Chemistry, Department of Pharmacology, University of North Carolina; Department of Materials Science & Engineering, North Carolina State University

Chemical cytometry, the application of high-sensitivity chemical separations to characterize the contents of single or small numbers of cells, is emerging as an important approach to profile signaling at the single-cell level.  These microelectrophoretic methods can perform direct measurements of the activity of normal or oncogenic kinases in single patient cells to aid in tumor cell characterization.

2:45 NanoVelcro-Embedded Microchips for Detection and Isolation of Circulating Tumor Cells: Validation Studies in Oncology Clinic

Hsian-Rong Tseng, Ph.D., Associate Professor, Department of Molecular and Medical Pharmacology, Crump Institute for Molecular Imaging, Institute for Molecular Medicine, University of California, Los Angeles; California NanoSystems Institute

Our team at UCLA has demonstrated a highly efficient, inexpensive cell-affinity assay (i.e., NanoVelcro Chips) capable of enriching, identifying and isolating CTCs in whole-blood samples collected from patients with different solid tumors. To further exploit the diagnostic values of CTCs, we have been working on a novel single-cell isolation technology, by coupling a NanoVelcro Chip with Laser MicroDissection (LMD) technique with a goal of enabling highly efficient and specific isolation of viable/preservative-free CTCs for sequential molecular and functional analyses.

Rarecells3:15 Molecular Analyses of CTC: Which View for Their Use to Improve Follow Up and Treatment of Patients with Cancer?  

Patrizia Paterlini-Brechot, Professor, Cell Biology & Oncology, University Paris Descartes, Paris; Director, INSERM Unit 807 & CSO, RarecellsBy using ISET, we have developed molecular methods targeted to CTC to identify non invasively theranostic mutations in patients with NSCLC and to perform NGS analyses. These advances will open the way to new exciting pathways to treat cancer patients.

3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall

(Last Chance for Poster Viewing)

4:35 The Ephesia Magnetic Arrays Technology, towards Quantitative High Content CTC Screening

Jean-Louis Viovy, Ph.D., Research Director, Macromolecules and Microsystems in Biology and Medicine Lab, Institute Curie

5:05 Digital Profiling of Circulating Tumor Cells: Towards Point-of-Care Molecular Diagnostics

Balaji Panchapakesan (Baloo), Ph.D., Associate Professor of Mechanical Engineering, University of Louisville

In this talk, we will present our efforts on developing hand held electronic devices for profiling molecular surface receptors directly in circulating tumor cells. The presentation will focus on our scientific efforts, opportunities and challenges faced in the development of new generation of electronic devices to profile circulating tumor cells for clinical applications.

NanoString5:35 Single-Cell Digital Gene Expression of 800 mRNA Targets: Applications for Circulating Tumor CellsJoseph M. Beechem, Ph.D., Senior Vice President, Research & Development, NanoString TechnologiesNanoString digital, multiplexed nucleic acid counting technology can now use single-cell input. 800-plex single-cell data will be shown, application to CTC's highlighted.

6:05 Advanced Platform for Real-Time Monitoring of Circulating Tumor Cells Beyond the Detection LimitsVladimir Zharov, Ph.D., D.Sc., Professor, Director, Arkansas Nanomedicine Center, University of Arkansas for Medical Sciences 

6:35 Close of Day

 

Day 1 | Day 2 | Day 3 



Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 Brochure cover 

Premier Sponsors:

Abbott Molecular 

 

Elsevier  


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large